echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Fosun Pharma's new coronavirus mRNA vaccine phase I clinical trial approved

    Fosun Pharma's new coronavirus mRNA vaccine phase I clinical trial approved

    • Last Update: 2020-07-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Guide: The vaccine is a biological product for prevention and is intended to be used mainly for the prevention of new coronavirus pneumonia in people aged 18 and over. on July 16,
    , Fosun Pharma announced that shanghai Fosun Pharmaceutical Industry Development Co., Ltd., a controlling subsidiary of the company, had received approval from the State Drug Administration for its new approved coronavirus mRNA vaccine (BNT162b1) for the prevention of new coronavirus pneumonia.
    Fosun Pharmaceuticals industry intends to conduct Phase I clinical trials of the vaccine in China (excluding Hong Kong, Macao and Taiwan, the same below) after the conditions are met.
    announced that fosun Pharmaceutical Industry in March 2020 by the German BioNTechSE authorized, in the region (i.e. Chinese mainland and Hong Kong, Macao and Taiwan, the same below) exclusive development, commercialization based on its proprietary mRNA technology platform developed for the new coronavirus vaccine products, BioNTech as the right person in the region.
    the vaccine is a biological product for prevention and is intended to be used mainly for the prevention of new coronavirus pneumonia in people aged 18 and over.
    as of the date of this announcement, the vaccine is in Phase I clinical trials in Germany and the United States, respectively, and no preventive vaccine developed on the mRNA technology platform has been approved for market worldwide.
    as of June 2020, the Group (i.e., the Company and its controlling subsidiaries/units) has invested approximately RMB14.06 million (unaudited; including licensing fees) in research and development of the vaccine at this stage.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.